Brooklyn Immunotherapeutics Inc
Change company Symbol lookup
Select an option...
BTX Brooklyn Immunotherapeutics Inc
SBCF Seacoast Banking Corporation of Florida
MSSAU Metal Sky Star Acquisition Corp
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Closing Price
$0.2303
Day's Change
-0.0319 (-12.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2993
Day's Low
0.2303
Volume
(Heavy Day)
Volume:
1,727,500

10-day average volume:
815,612
1,727,500

Thinking about buying stock in Toughbuilt Industries, Exela Technologies, Bausch Health, Fluence Energy, or Evofem Biosciences?

8:32 am ET July 29, 2022 (PR Newswire) Print

InvestorsObserver issues critical PriceWatch Alerts for TBLT, XELA, BHC, FLNC, and EVFM.

https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

-- TBLT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=TBLT&prnumber=072920221

-- XELA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=XELA&prnumber=072920221

-- BHC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BHC&prnumber=072920221

-- FLNC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=FLNC&prnumber=072920221

-- EVFM: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=EVFM&prnumber=072920221

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

https://c212.net/c/img/favicon.png?sn=CG31170&sd=2022-07-29

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-toughbuilt-industries-exela-technologies-bausch-health-fluence-energy-or-evofem-biosciences-301596082.html

SOURCE InvestorsObserver

https://rt.prnewswire.com/rt.gif?NewsItemId=CG31170&Transmission_Id=202207290832PR_NEWS_USPR_____CG31170&DateId=20220729

comtex tracking

COMTEX_411229499/1005/2022-07-29T08:32:07

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.